10 Points On Dostarlimab, The Drug That 'Cured' Cancer During Trials - dofaq.co
10 Points On Dostarlimab, The Drug That 'Cured' Cancer During Trials
What is Dostarlimab?
Neoadjuvant Dostarlimab Eradicates Disease in 82% of Mismatch Repair–Deficient Solid Tumors
Dostarlimab: Review on success story and clinical trials
Dostarlimab-gxly Granted Breakthrough Therapy Designation for Rectal Cancer
GSK's Jemperli (dostarlimab) plus chemotherapy approved in Singapore as the first frontline immuno-oncology treatment for dMMR/MSI-H primary advanced or recurrent endometrial cancer dostarlimab ) plus chemotherapy approved in Singapore as the first frontline immuno-oncology treatment for dMMR/MSI-H primary advanced or recurrent endometrial cancer ...
FDA Grants Dostarlimab Breakthrough Therapy Designation in dMMR/MSI-H Rectal Cancer
A New Immune Treatment May Work Against Several Cancer Types
STARKAP Protocol: preliminary assessment of safety and tolerability of dostarlimab in combination antiretroviral therapy (cART)-refractory HIV associated Kaposi’s Sarcoma dostarlimab in combination antiretroviral therapy (cART)-refractory HIV associated Kaposi’s Sarcoma ...
CITRINO: phase 1 dose escalation study of anti-LAG-3 antibody encelimab alone or in combination with anti-PD-1 dostarlimab in patients with advanced/metastatic solid tumours dostarlimab in patients with advanced/metastatic solid tumours ...
Jemperli (dostarlimab), MAH: GlaxoSmithKline (Ireland) Limited dostarlimab ), MAH: GlaxoSmithKline (Ireland) Limited ...
Dostarlimab/Chemo Improves Long-Term DOR in Advanced Endometrial Cancer
Dostarlimab Combo Earns Expanded European Approval in Endometrial Cancer
Efficacy and safety of dostarlimab in combination with chemotherapy in patients with dMMR/MSI-H primary advanced or recurrent endometrial cancer in a phase 3, randomized, placebo-controlled trial (ENGOT-EN6-NSGO/GOG-3031/RUBY) dostarlimab in combination with chemotherapy in patients with dMMR/MSI-H primary advanced or recurrent endometrial cancer in a phase 3, randomized, placebo-controlled trial (ENGOT-EN6-NSGO/GOG-3031/RUBY) ...
Real-World Analysis Confirms Efficacy/Safety of Dostarlimab Plus Chemotherapy in Advanced Endometrial Cancer
European Commission Approves Dostarlimab Plus Chemo for All Advanced/Recurrent Endometrial Cancer
Dr Lantsman on Future Directions for Evaluating Dostarlimab/Chemo in Endometrial Cancer
FDA Grants Breakthrough Therapy Designation to Dostarlimab for dMMR/MSI-H Rectal Cancer
Dostarlimab/Chemo Earns Expanded Canadian Approval in Primary Advanced, First Recurrent Endometrial Cancer
Dostarlimab Plus Chemo With Maintenance Niraparib Generates Modest PFS Boost in Advanced Ovarian Cancer
